4//SEC Filing
Hannah Brendan 4
Accession 0000912282-25-001370
CIK 0001662774other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 8:12 AM ET
Size
10.7 KB
Accession
0000912282-25-001370
Insider Transaction Report
Form 4
Hannah Brendan
CBO, COO & CCO
Transactions
- Exercise/Conversion
Common Shares
2025-12-05$0.55/sh+2,271$1,249→ 336,547 total - Exercise/Conversion
Common Shares
2025-12-05$0.94/sh+25,280$23,763→ 361,827 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-12-05−2,271→ 45,168 totalExercise: $0.55Exp: 2032-05-22→ Common Shares (2,271 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-12-05−25,280→ 199,720 totalExercise: $0.94Exp: 2033-01-31→ Common Shares (25,280 underlying)
Footnotes (2)
- [F1]Represents grant of 103,500 employee stock options on May 19, 2022, which vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.
- [F2]Represents grant of 225,000 employee stock options on February 2, 2023, which vest in equal monthly installments at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, with full vesting on the fourth annual anniversary of the vesting commencement date.
Documents
Issuer
Quince Therapeutics, Inc.
CIK 0001662774
Entity typeother
Related Parties
1- filerCIK 0001929422
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 8:12 AM ET
- Size
- 10.7 KB